Evaluation of prognostic value of vascular endothelial growth factor and endocan in non-small cell lung cancer
Open Access
- 12 December 2025
- journal article
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (6) , 1424-1434
Abstract
Background/aim: No reliable, easily measurable biomarker currently exists for the screening or prognosis of lung cancer. The present study evaluates the potential utility of vascular endothelial growth factor (VEGF) and endocan, which can be readily measured in blood samples, as biomarkers for screening and prognostic assessment in lung cancer. Materials and methods: Included in the study were 38 patients with early-stage non-small cell lung cancer (NSCLC) and 29 controls. All patients underwent surgical intervention and were monitored for 1 month postoperatively. Serum VEGF and endocan levels were measured preoperatively and postoperatively. Clinical characteristics, laboratory data, and histopathological findings were recorded for all participants. Results: The preoperative VEGF levels of the patients were significantly higher than those of the controls (p = 0.001), while postoperative VEGF levels decreased significantly following surgery (p < 0.001). The endocan levels of the patients and controls were similar preoperatively. Additionally, endocan levels were significantly increased after the surgery in the patient group (p < 0.001). A comparison of VEGF and endocan levels according to TNM staging and tumor histopathology revealed no significant differences. Conclusion: VEGF can serve as a potential biomarker for screening and prognostic assessment in early-stage NSCLC. In contrast, endocan did not demonstrate utility for such clinical purposes. VEGF may also be considered for the evaluation of treatment efficacy following surgical intervention.Keywords
This publication has 44 references indexed in Scilit:
- Vascular endocan is preferentially expressed in tumor endotheliumMicrovascular Research, 2006
- Endocan Expression and Relationship with Survival in Human Non–Small Cell Lung CancerClinical Cancer Research, 2006
- Serum Vascular Endothelial Growth Factor (VEGF) and Interleukin-8 (IL-8) Levels in Small Cell Lung CancerCancer Investigation, 2006
- Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2006
- Role of Serum Vascular Endothelial Growth Factor in the Prediction of Angiogenesis and Prognosis for Non-small Cell Lung CancerLung, 2005
- The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patientsRespiratory Medicine, 2004
- Overexpression of endocan induces tumor formation.2003
- Clinical significance of vascular endothelial growth factor in patients with primary lung cancerRespirology, 2002
- Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte countsLung Cancer, 2001
- Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinomaThe Journal of Thoracic and Cardiovascular Surgery, 1998